# Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation

> **NCT01035593** · PHASE2 · WITHDRAWN · sponsor: **Pharming Technologies B.V.**

## Conditions studied

- Graft Rejection
- Kidney Transplantation

## Interventions

- **PROCEDURE:** plasmapheresis and IVIG
- **DRUG:** recombinant C1 inhibitor

## Key facts

- **NCT ID:** NCT01035593
- **Lead sponsor:** Pharming Technologies B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-12
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Recent improvements in clinical practice have reduced the apparent incidence of AMR in renal transplantation.
- **Last updated:** 2012-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01035593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01035593, "Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01035593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*